Tag: Ionis

February 25, 2019 Off

Novartis taking over responsibility of cardiovascular therapy agent TQJ230 from Akcea Therapetuics

Novartis will exercise its option for worldwide responsibility of TQJ230, an investigational agent for targeted cardiovascular therapy previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals.

January 6, 2017 Off

Novartis and Ionis team on cardiovascular treatments

By Dino Mustafić

Novartis and Ionis Pharmaceuticals with its affiliate Akcea Therapeutics have signed an agreement for licensing two novel treatments for reducing cardiovascular risk in patients with high levels of lipoproteins known as Lp(a) and ApoCIII.